Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Epilepsy Res ; 140: 111-119, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29331845

RESUMO

Levetiracetam (LEV) is an anticonvulsant drug with a unique mechanism of action that is not completely understood. However, its activity profile may involve effects on excitatory and/or inhibitory neurotransmission since the primary target of LEV, synaptic vesicle protein 2A, is ubiquitously expressed in all types of synaptic vesicles. Therefore, the objective of the present study was to explore the effect of LEV (300 mg/kg/day for one week, administered via osmotic mini-pumps) on neurotransmitter release and its probable selective effect on extracellular gamma-amino butyric acid (GABA), glutamate (Glu), aspartate (Asp), glutamine (Gln), taurine (Tau) and glycine (Gly) concentrations (using in vivo microdialysis under basal and high-K+ conditions) in the dorsal hippocampus (DH), a region that undergoes major synaptic changes during epilepsy. Epileptic rats developed clear signs of hyperexcitability, i.e., an elevated Glu/GABA ratio in the DH. The LEV concentration in blood after 7 days of treatment was within the therapeutic range. In contrast, LEV was not detected four days after mini-pump removal (washout period). Furthermore, LEV restored the Glu/GABA ratio to approximately the control level and significantly increased the GABA concentration after the initiation of high-K+ conditions. Based on these data, LEV treatment restored the lost balance between the excitatory and inhibitory systems under basal conditions. Moreover, LEV showed a selective effect by preferentially increasing vesicular release of GABA, a mechanism by which LEV could reduce epileptic seizures.


Assuntos
Aminoácidos/metabolismo , Anticonvulsivantes/farmacologia , Epilepsia do Lobo Temporal/tratamento farmacológico , Hipocampo/efeitos dos fármacos , Levetiracetam/farmacologia , Animais , Anticonvulsivantes/sangue , Modelos Animais de Doenças , Epilepsia do Lobo Temporal/metabolismo , Espaço Extracelular/efeitos dos fármacos , Espaço Extracelular/metabolismo , Hipocampo/metabolismo , Levetiracetam/sangue , Masculino , Pilocarpina , Distribuição Aleatória , Ratos Wistar
3.
Bioanalysis ; 6(21): 2815-24, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25486229

RESUMO

BACKGROUND: Sildenafil is used for the treatment of pediatric pulmonary hypertension. A dried blood spot (DBS)-based LC-MS method for sildenafil quantitation was developed and applied to a group of patients. RESULTS: DBS showed high portability and stability of samples, and the method was selective and linear for quantitation of sildenafil (5-3,000 ng/ml) and N-desmethyl-sildenafil (3-1,500 ng/ml). After a single oral dose of sildenafil (1 mg/kg), method evidenced poor metabolism in these patients. CONCLUSION: The method was successfully applied in peripheral blood and can be used for both pharmacokinetics and therapeutic drug monitoring. DBS proved to have advantages during sample translation and preservation of analytes. Data suggest that hazardous blood sildenafil levels may be reached in this population.


Assuntos
Cromatografia Líquida de Alta Pressão , Piperazinas/sangue , Sulfonamidas/sangue , Espectrometria de Massas em Tandem , Vasodilatadores/sangue , Criança , Pré-Escolar , Teste em Amostras de Sangue Seco , Monitoramento de Medicamentos , Feminino , Meia-Vida , Humanos , Hipertensão Pulmonar/tratamento farmacológico , Masculino , Piperazinas/farmacocinética , Piperazinas/uso terapêutico , Purinas/sangue , Purinas/farmacocinética , Purinas/uso terapêutico , Citrato de Sildenafila , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapêutico , Vasodilatadores/farmacocinética , Vasodilatadores/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA